Register Login
Welcome to the Fritsma Factor

Please join our
hemostasis discussions.

George Fritsma

MS, MLS, Lab Scientist, Educator, Author

George Fritsma is a medical laboratory scientist, educator, and author. George contributed 10 chapters to Keohane EM, Smith LJ, Walenga JM: Rodak’s Hematology; Clinical Principles and Applications, Fifth Edition, 2015, Elsevier; and is the co-author of Bennett A, Fritsma GA, Ernst DJ: Quick Guide to Blood Collection Edition 2, 2016, Marques MB, Fritsma GA: Quick Guide to Coagulation Testing Edition 3, 2015, and Reddy V, Marques MB, Fritsma GA: Quick Guide to Hematology Testing Edition 2, 2013, along with three additional titles, all published by AACC Press. He is a consultant in Laboratory Medicine, Department of Pathology at the University of Alabama at Birmingham where he developed uabcoag.net. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

read more

Most Recent

September 2024 Quick Question: PTT

I (Geo) prefer PTT to APTT or aPTT because the “A” or “a” is superfluous.  Laboratory scientists no longer offer an “unactivated” PTT. The “partial thromboplastin” reagent consists of a phospholipid or combination of phospholipids that may include animal, plant, or synthetic sourced phosphatidylserine, phosphatidylcholine, phosphatidylinositol, sphingomyelin, and/or phosphatidylethanolamine. Accompanying the phospholipid is one of […]
read more

August 2024 Quick Question Summary: Rebalancing Therapy

Our August 2024 Quick Question, which attracted 18 responses, asked, “Which hemophilia ‘rebalancing’ therapy suppresses antithrombin RNA production?” Here are your answers: Efanesoctocog alfa: 0 Concizumab: 3 (17%) Octavian 2 (11%) Hemgenix 3 (17%) Fitusiran 10 (55%) Rebalancing therapy is the name for using RNA inhibitors (RNAi) that suppress mRNA synthesis, subsequently suppressing selected molecules. […]
read more

Extended Life Cryoprecipitate Fibrinogen

As reported by Amy Carpenter quoting Jay Hudgins, DO, MS, director of hemostasis and thrombosis, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio, USA in the August 2024 edition of CAP Today, extended-life cryoprecipitate has several applications. INTERCEPT®, is the Cerus, Inc. trademark for their materials that crosslink and inactivate bacterial and […]
read more

A Molecular Approach to Assess Platelet Hyperreactivity

Friend Ed Groenendal forwarded this UPI summary of a molecular approach correlating evidence of hyperresponsive platelets to major adverse cardiac or limb events. The investigators started with aggregometry-defined platelet hyperreactivity to apply a transcriptome-based platelet reactivity expression score (PRESS). Click below to see the detailed open-access article describing the development and application of the PRESS. […]
read more

Questions or Comments?